FDA 483 - Sun Pharmaceutical Industries Limited - March 17, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Sun Pharmaceutical Industries Limited in New Delhi, India, was cited during an FDA inspection of its Biopharmaceutics Clinical Facility for significant data integrity and submission issues. The firm failed to include critical addendums to clinical study reports in an abbreviated new drug application and could not provide original electronic study documentation for review due to a global information security incident. These observations indicate deficiencies in data management and regulatory submission practices.
ID · 91b1aeaa-7c53-4a53-bce1-a8443bffca39